focus -WSS

focus

author：hotspot 2025-10-01 15:28:59 - browse：3

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Humana cuts profit projections as Medicare Advantage costs soar

WSS

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Parkinson’s finding may lead to tests and, someday, treatments

Research misconduct: Proposed new rules face resistance

Creating egg and sperm cells from stem cells raises ethical issues

UnitedHealth increases loan offers after Change Healthcare outage

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Medicare details structure of new drug price negotiation program

Research misconduct: Proposed new rules face resistance

The high cost of giving birth even with insurance

Physicians and social media: If you see something, say something?

How to save PrEP access — and even expand it

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Test for long Covid? Researchers find new clue in blood samples

In Memoriam: Notable people who died in 2023

EU regulator recommends expanding Mounjaro approval to obesity

Wikipedia

Elizabeth Holmes banned from government health programs

Eli Lilly, Pfizer, and others want in on the online prescription market

NIH director takes cautious approach to Biden drug pricing priority

The tragedy of Johnson & Johnson’s Covid vaccine

eGenesis tests gene

Virtual Event: March of the Biosimilars

knowledge

focus

leisure time

explore